Vedolizumab, currently widely used in clinical practice, has demonstrated substantial efficacy and a favorable safety profile in the treatment of IBD by selectively targeting the α4β7 integrin-MAdCAM-1 pathway. This evidence concerns the gene MADCAM1 and inflammatory bowel disease.